Literature DB >> 2379870

Effect of the immune modulating agents cyclophosphamide, methotrexate, hydrocortisone, and cyclosporin A on an animal model of granulomatous bowel disease.

I C Mitchell1, J L Turk.   

Abstract

This study was undertaken to determine the effect of cyclophosphamide, methotrexate, hydrocortisone, and cyclosporin A on a model of granulomatous infiltration in the terminal ileum and draining lymph nodes of the guinea pig. Treatment groups of six animals were used and compared to untreated groups of 12. Epithelioid cell granulomas and primary macrophage granulomas were induced by the inoculation of BCG (Pasteur) and irradiated Mycobacterium leprae respectively into the terminal ileum of the guinea pig. The response to purified protein derivative of tuberculin was reduced in both groups of animals receiving any of these agents. Cyclophosphamide and methotrexate treated animals inoculated with BCG or M leprae showed a significant reduction of granulomatous infiltration at the inoculation site (p less than 0.05 and p less than 0.001 respectively). BCG inoculated animals treated with either hydrocortisone or cyclosporin A showed no reduction in granulomatous infiltration at either the inoculation site or the draining lymph nodes. By contrast M leprae inoculated animals receiving either of these agents showed a significant reduction of granulomatous infiltration at both the inoculation site (p less than 0.001) and in the primary draining lymph node (p less than 0.001). Ziehl Neelsen staining showed an increased proportion of animals with detectable acid fast bacilli (AFB) at the inoculation site in the groups receiving hydrocortisone (50%) and methotrexate (67%) compared to untreated controls (8%). No AFB were observed in any of the animals inoculated with M leprae. In conclusion, this model may be helpful in elucidating the mechanism of T lymphocyte response in Crohn's disease and the variable clinical response seen with the use of immunosuppressive agents in this condition.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2379870      PMCID: PMC1378494          DOI: 10.1136/gut.31.6.674

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  23 in total

1.  Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Gastroenterology       Date:  1986-10       Impact factor: 22.682

2.  Site of action of cortisol in cellular immunity.

Authors:  W L Weston; H N Claman; G G Krueger
Journal:  J Immunol       Date:  1973-03       Impact factor: 5.422

3.  Treatment of Crohn's disease in relapse with cyclosporin A.

Authors:  N R Parrott; R M Taylor; C W Venables; C O Record
Journal:  Br J Surg       Date:  1988-12       Impact factor: 6.939

4.  Skin granuloma formation in mice immunosuppressed by cyclosporine.

Authors:  H Suya; A Fujioka; C Pincelli; K Fukuyama; W L Epstein
Journal:  J Invest Dermatol       Date:  1988-04       Impact factor: 8.551

5.  Immunosuppressive effects of glucocorticosteroids: differential effects of acute vs chronic administration on cell-mediated immunity.

Authors:  J E Balow; D L Hurley; A S Fauci
Journal:  J Immunol       Date:  1975-03       Impact factor: 5.422

6.  Effects of in vivo treatments with cyclosporin-A on mouse cell-mediated immune responses.

Authors:  S Alberti; D Boraschi; W Luini; A Tagliabue
Journal:  Int J Immunopharmacol       Date:  1981

7.  Analysis of cells of the mononuclear phagocyte series in experimental mycobacterial granulomas by monoclonal antibodies.

Authors:  R C Mathew; I Katayama; S K Gupta; J Curtis; J L Turk
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

8.  Cyclosporin for Crohn's disease.

Authors:  M C Allison; R E Pounder
Journal:  Aliment Pharmacol Ther       Date:  1987-02       Impact factor: 8.171

9.  Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.

Authors:  D Bunjes; C Hardt; M Röllinghoff; H Wagner
Journal:  Eur J Immunol       Date:  1981-08       Impact factor: 5.532

10.  Glucocorticoid suppression of macrophage migration inhibitory factor.

Authors:  J E Balow; A S Rosenthal
Journal:  J Exp Med       Date:  1973-04-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Cyclosporin for Crohn's disease?

Authors:  M Guslandi; A Tittobello
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

2.  Observations on the Kveim reaction using an animal model of granulomatous bowel disease.

Authors:  I C Mitchell; J L Turk
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

3.  Intractable Crohn's colitis and perianal disease responding to cyclophosphamide and epirubicin.

Authors:  N Rieger; J Stahl; D Wattchow
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

Review 4.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.